Other languages Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Market Closed - Nasdaq Other stock markets 21:30:01 03/05/2024 BST			5-day change	1st Jan Change
0.4115 ^USD	-2.30%		-12.35%	-28.43%

02-29	Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
01-22	Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-29
Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid	01-22
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID	01-02
Virios Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13
Virios Therapeutics, Inc. Announces Termination of At-The-Market Sales Agreement	18/09/23
Virios Therapeutics Shares Slump After Company Reports Q2 Loss	10/08/23
Virios Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23
Virios Therapeutics, Inc. Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as A New Treatment Option for Fibromyalgia	09/08/23
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-Covid Symptoms Following Treatment with A Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study	17/07/23
Virios Therapeutics Regains Compliance With Nasdaq Listing Rule	26/05/23
Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23
Virios Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	14/03/23
Virios Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	14/03/23
Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023	13/02/23
Better-Than-Expected Inflation Data Seen Boosting US Equities	13/12/22
US Stock Futures Move Higher Ahead of November Inflation Data	13/12/22
Virios Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
Sector Update: Health Care Stocks Struggle on Tuesday	20/09/22
Sector Update: Health Care Stocks Dropping in Afternoon Trade	20/09/22
Sector Update: Health Care	20/09/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Other languages

Filters